the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
There are two studies included in this protocol. One is an open-label Phase Ⅱ study . The other is a multi-center, double-blind, randomized, phase III study .
Hepatocellular Carcinoma
DRUG: Rulonilimab+Lenvatinib|DRUG: Rulonilimab placebo +Lenvatinib
ORR, Objective Response Rate (ORR) Based on RECIST 1.1 Assessed by Independent Review Committee(IRC), From randomization to PR or CR.Up to approximately 35 months.
PFS, Progression-free survival (PFS) evaluated by the Blinded Independent Central Review, From randomization to the first documented disease progression or death due to any cause, whichever occurs first.Up to approximately 35 months.|OS, Overall survival (OS), From date of randomization until the date of death from any cause.Up to approximately 35 months.
There are two studies included in this protocol. One is an open-label Phase Ⅱ study designed to evaluate the tolerability and safety of lenvatinib in combination with Rulonilimab in participants with hepatocellular carcinoma (HCC). The other is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Rulonilimab in combination with lenvatinib and placebo in combination with lenvatinib in the treatment of subjects with no prior systemic treatment and with unresectable advanced hepatocellular carcinoma (HCC).